Capstone Therapeutics Corp. — FY2015 Form 10-K Summary
Business context and reporting period
The filing is for the fiscal year ended December 31, 2015. The source filing identifies the registrant as Capstone Therapeutics Corp., not Capstone Holding Corp. Capstone is a development-stage biotechnology company with no commercial products or revenue-generating operations. Its principal remaining asset is a 60% interest in LipimetiX Development, Inc., which is developing the Apo E mimetic peptide AEM-28 and analogs, including lead candidate AEM-28-14.
The Company operates under a virtual model with two full-time administrative employees and consultants. AEM-28 Phase 1a and Phase 1b/2a trials were completed in 2014; limited development work continued in 2015.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | No commercial revenue |
| General and administrative expense | $1.757 million | $1.453 million | +$0.304 million |
| Research and development expense | $1.182 million | $3.071 million | -$1.889 million |
| Total operating expenses | $2.939 million | $4.524 million | -$1.585 million |
| Net loss | $2.771 million | $4.167 million | Loss reduced by $1.396 million |
| Basic and diluted loss per share | $0.07 | $0.10 | Improved |
| Cash flow from operations | $(2.153) million | $(4.094) million | Use reduced by $1.941 million |
| Cash and cash equivalents at year-end | $1.011 million | $2.164 million | -$1.153 million |
| Convertible notes payable | $1.000 million | None reported | New borrowing |
| Accumulated deficit | $188.956 million | $186.185 million | Increased by $2.771 million |
Gross margin and operating margin are not meaningful because the Company reported no revenue. The filing does not provide a clear standalone cash runway estimate. Total assets were $1.767 million, total current liabilities were $261,000, and total equity was $506,000 at December 31, 2015.
The Company advanced approximately $1.510 million to the joint venture under a revolving loan agreement. The advance was due December 31, 2016 and exceeded the stated net funding limit described elsewhere in the filing. The Company also contributed $6.0 million to the joint venture since formation.
Material changes versus the prior comparable period
- Research and development expense declined substantially as the joint venture’s initial clinical development plan had been substantially completed in 2014; 2015 joint venture operating expenses were approximately $959,000 before intercompany eliminations.
- General and administrative expense increased because of qui tam litigation costs, preparation of a Form S-1 registration statement, and investor relations activity.
- Operating cash use and net loss decreased primarily because of lower development spending.
- Cash declined to approximately $1.0 million despite $1.0 million of financing proceeds from convertible promissory notes.
- In June 2015, LipimetiX converted from a limited liability company to a corporation.
- The Company filed a Form S-1 in June 2015, but it was not effective at year-end and was withdrawn in January 2016.
- The Company granted options to purchase 1.210 million shares in 2015; total options outstanding increased to 4.163 million at year-end.
Guidance, outlook, risks and unusual items
Management stated that additional funding is required to continue operations and materially advance AEM-28 or its analogs. The Company is exploring fundraising, partnering, licensing, strategic transactions, and potential merger-related alternatives. Without new funding, development is expected to remain limited and the Company may be unable to continue as a going concern.
The filing states that substantial doubt exists regarding the Company’s ability to continue as a going concern. The Company expects continuing losses and does not expect pharmaceutical products or revenue for at least several years, if ever.
- The $1.0 million convertible notes bear interest at 5% and mature April 30, 2017. They may convert upon a qualifying equity financing or at lender election under specified conditions.
- The lenders declined in January 2016 to extend the exclusive period or proceed with a proposed additional investment of $7.5 million to $10.0 million.
- The Company filed the 2015 Form 10-K without an independent public accountant’s audit opinion because of cash constraints. Management warned that this may adversely affect SEC compliance, OTCQB eligibility, trading liquidity, and financial viability.
- The 2015 and 2014 financial statements are marked unaudited in the filing.
- The joint venture’s minority stockholders appoint a majority of its board, despite the Company’s 60% economic ownership, limiting the Company’s control over operations.
- The joint venture has no sufficient funding for additional material development activities, and future clinical work depends on regulatory approvals and financing.
- Key risks include clinical or preclinical failure, regulatory delays or rejection, competition, intellectual-property challenges, dependence on consultants and third parties, product liability, and inability to commercialize or recover the Company’s joint venture investment.
- The Company settled a long-pending qui tam lawsuit in June 2015 for a one-time $50,000 payment.
- The Company recorded a $192,000 Australian refundable research and development tax credit in 2015.
Most important facts for investors to verify
- Confirm the registrant’s legal name and ticker; the filing identifies Capstone Therapeutics Corp. and OTCQB symbol CAPS.
- Review the absence of an independent audit opinion and assess the resulting SEC and OTCQB compliance implications.
- Verify current cash, debt maturity, interest, conversion terms, collateral, and any subsequent financing.
- Assess whether the Company obtained funding sufficient to continue operations and the joint venture’s development program after December 31, 2015.
- Evaluate the recoverability of the $6.0 million joint venture investment and approximately $1.510 million revolving advance.
- Review subsequent events, including the January 2016 withdrawal of the Form S-1 and the lenders’ decision not to pursue the proposed investment.
- Confirm the clinical, regulatory, patent, and partnering status of AEM-28-14 and related analogs.
- Consider dilution from 4.163 million outstanding options, additional warrants, convertible notes, and any future equity financing.